THE APEX TIMES
New Phase 3b data from an open-label study track symptoms, patient-reported outcomes, and metabolic measures over one year for adults living with both psoriatic arthritis and obesity.
Eli Lilly (NYSE: LLY) said it has released detailed 52-week results from a Phase 3b open-label study evaluating whether combining its psoriasis and psoriatic arthritis medicine Taltz with its obesity treatment Zepbound can improve outcomes in adults who have both conditions. Lilly presented the findings as part of TOGETHER-PsA, a program designed to assess the effects of using the therapies together rather than separately in the same patients.
In its announcement tied to the one-year results, Lilly said the combination showed improved and durable efficacy through the 52-week mark. The company also said the study measured outcomes beyond clinical response, including patient-reported results, which capture how patients experience changes in symptoms and daily functioning, and metabolic outcomes, which track biological or lab-related measures linked to weight and related health risks.
Lilly’s news release describes TOGETHER-PsA as a Phase 3b open-label trial, meaning both patients and researchers know which treatments are being given. The company framed the 52-week readout as a way to examine whether the effects of pairing Taltz and Zepbound persist over time, a point that can matter for chronic diseases where benefits must hold beyond early treatment windows.
The study population, according to Lilly’s description, includes adults with psoriatic arthritis and obesity. That combination of diagnoses is clinically relevant because weight can worsen inflammation and joint symptoms, while inflammatory disease can complicate weight management, creating a potential incentive to treat both pathways at the same time.
Lilly’s two medicines represent different therapeutic categories in its portfolio. Taltz (ixekizumab) is positioned by the company for immune-mediated inflammatory conditions, including those in the psoriasis and psoriatic arthritis spectrum. Zepbound (tirzepatide) is positioned for obesity treatment, typically used to support weight reduction and related metabolic improvements. In TOGETHER-PsA, Lilly is testing whether the overlap between these areas translates into measurable improvements for patients who face both sets of challenges.
Industry analysts typically watch combination studies for two reasons: durability and breadth of outcomes. Lilly’s framing of the 52-week data suggests the company is aiming to show not only that efficacy continues, but also that patients report benefits and that metabolic measures move in the right direction when the therapies are used together.
The publicly available reporting around the announcement did not lay out specific response rates, mean changes, or the magnitude of the patient-reported or metabolic outcomes. It also did not provide additional detail in the excerpt level reporting about safety metrics or subgroup results, which are often critical for interpreting real-world value in chronic combination regimens.
Looking ahead, investors and clinicians are likely to focus on what Lilly will disclose next, including the full set of efficacy statistics, how durability is defined in the trial, and the safety profile of long-term concomitant use. If Lilly can substantiate sustained benefit across both clinical endpoints and patient-reported and metabolic measures, TOGETHER-PsA could strengthen the case for multi-target treatment strategies in psoriatic disease complicated by obesity.
A strong quarter from CoreWeave, a major cloud provider for AI compute, helped quiet worries that technology infrastructure spending could cool. Shares tied to AI chips and networking moved higher alongside the sentiment shift.
The ride-hailing and delivery platform is expanding an expanded McDonald’s partnership across 14 markets, positioning delivery growth as a lever for broader Uber Direct adoption and customer engagement.
A major downgrade cut Nvidia’s target price by about 60 percent, while other Wall Street analysts held bullish outlooks and pointed to higher upside targets.
A Bank of America analyst adjusted Eli Lilly’s price target, saying attention should broaden beyond the company’s weight-loss blockbuster franchise as it prepares for its December Innovation Day.
A new report says Tesla and SpaceX have each formed special committees to review a potential all-stock merger, a move that comes as Tesla prepares to unveil its next-generation Roadster.
A new report says Visa is integrating with Monad to expand the flexibility of its stablecoin settlement network, pointing to surging settlement activity and growing institutional interest in faster, programmable payment flows.
Bank of America sees upside in Qualcomm’s efforts to position the chipmaker as a broader supplier to AI data centers, while still expressing caution on what near-term execution can deliver.
A Wall Street note captured a split view of Advanced Micro Devices, with higher profit expectations offset by a lower price target amid recent market pressure.
A Yahoo Finance report says Cathie Wood’s ARK Investment Management reduced its Amazon position while adding to a basket of aerospace-related names after strong trading activity around a rocket launch company.
A recent pullback has renewed debate over whether Exxon Mobil’s valuation properly reflects its current deal slate, including new activity tied to Venezuela, despite the company’s strong multi-year run.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...